相关实验视频

Updated: Jun 17, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

减少多发性硬化症疾病修饰疗法的升级 - - 丹麦全国性队列研究

Frederik Elberling¹, Mie Reith Mahler¹, Luigi Pontieri¹

¹The Danish Multiple Sclerosis Registry, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.

European journal of neurology

|February 3, 2025

概括

将多发性硬化症 (MS) 治疗从高疗效 (HE) 降低到中等疗效 (ME) 疗法,对于大多数患者来说,无法保持疾病的稳定性. 年龄较小和先前的炎症活动增加了降级后的疾病活动.

科学领域:

神经学神经学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

高效 (HE) 疾病修饰疗法 (DMT) 是多发性硬化症 (MS) 的标准.
人们对HE DMT的疗效和老年多发性硬化症患者的不良事件存在担忧.
降级到中度有效性 (ME) 的DMT是一种潜在的策略.

研究的目的:

在MS患者从HE降级到ME DMTs后评估疾病活性和治疗轨迹.
为了确定疾病活动降级后的风险因素.

主要方法:

使用丹麦多发性硬化病注册表 (DMSR) 进行的队列研究.
包括复发性复发性多发性硬化症 (RRMS) 患者从HE切换到ME DMT (2007年10月至2023年7月).
随访时间中位数为0.8年.

主要成果:

333名患者的病情下降,大多数从纳塔利祖马布/芬戈利莫德转变为二甲基烟酸.
2年后复发的累积风险为38%.
2年后,炎症活动 (复发/放射学) 的累积风险为53%.
年轻的年龄和先前的炎症活动预测了降级后的疾病活动.

结论:

从纳塔利祖马布和芬戈利莫德降级到ME DMTs对MS疾病稳定性并不始终有效.
年轻的年龄和前降级炎症活动是未来疾病活动的关键风险因素.
结果可以为未来的降级策略和MS管理研究提供信息.

关键词:

这是DMT DMT.在MSMSMSMSMSMSMSMSMS中,我们可以看到年龄的年龄年龄的年龄.高效的治疗疗法具有很高的疗效.适度有效的治疗疗法风险是利益,风险是利益.治疗策略治疗策略治疗切换器治疗切换器

更多相关视频

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

相关概念视频

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...